Orthofix lowers 2026 guidance as Q3 net sales rise 1% to $207.9 million

Orthofix reported third-quarter 2026 net sales of $207.9 million, up 1.1% from $205.6 million a year earlier, and a net loss of $6.1 million, narrowed from $22.8 million. The company lowered its full-year 2026 net sales guidance to $825 million to $830 million from $845 million to $855 million, and its adjusted EBITDA guidance to $86 million to $88 million from $95 million to $98 million, citing weaker U.S. Spine performance.

Key points

• Q3 2026 net sales were $207.9 million, up 1.1% reported and 2.3% pro forma constant currency; Global Limb Reconstruction rose 8.5% and Spinal Implants, Biologics and Enabling Technologies fell 1.1%.
• Q3 net loss was $(6.1) million, or $(0.15) per share, versus $(22.8) million, or $(0.57) per share, a year earlier; adjusted EBITDA was $26.0 million versus $24.6 million.
• 2026 net sales guidance was cut to $825 million–$830 million; adjusted EBITDA guidance was cut to $86 million–$88 million.
• Cash, cash equivalents and restricted cash were $86.9 million at September 30, 2026, down from $104.4 million at June 30, 2026.

The filing

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:25 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.